Telomerase is a ribonucleoprotein complex the function of which is to add telomeric repeats (TTAGGG) n to chromosomal ends, and it is known to play an important role in cellular immortalization. Telomerase is highly active in most tumor cells, yet not in normal cells. As such, it may have possible applications in cancer gene therapy. Telomerase consists of two essential components, telomerase RNA template (hTR) and catalytic subunit (hTERT). hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor and fetal cells. We here tested the possibility of the utilization of the hTERT promoter in targeted cancer gene therapy. We cloned the hTERT promoter in the replace of the CMV promoter and sub-cloned HSV-TK gene to be controlled by hTERT gene promoter in adenovirus shuttle plasmid. Then we constructed recombinant adenovirus Ad-hT-TK, and infected them into normal and human gynecological cancer cell lines. Through these experiments, we identiˆed the selective tumor speciˆc cell death by Ad-hT-TK. Furthermore, FACS analysis and TUNEL assay suggests that the reduced viability is mediated through the induction of apoptosis, indicating that this approach may be a useful method for suppressing cancer growth in targeted cancer gene therapy. These results show that Ad-hT-TK could be used for gynecological cancer gene therapy.
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Ovarian cancer accounts for only 4z of cancers in women, but it is the leading cause of death from gynecological malignancies in Western countries. 1) Since ovarian cancer tends to be asymptomatic until it is well advanced, it is di‹cult to diagnose in early stages.
Telomerase is highly active in both small-cell and non-small-cell lung cancers, 2) colorectal and gastric cancers, 3) hepatocellular carcinomas, 4) hematologic malignancies, 5) giant cell tumors of bone, 6) prostate cancers, 7) breast cancers, 8) and ovarian carcinomas.
9)
Telomerase is a ribonucleoprotein, which consists of several components. Among these, two components are known of their functions: the RNA component (hTR) and the telomerase catalytic subunit (hTERT). hTR acts as a template for telomere synthesis. 10) The expression of hTR is ubiquitous in all types of human cells, regardless of the status of telomerase activity, but hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor and fetal cells. [11] [12] [13] Recently, the promoter region of cancer speciˆc human telomerase reverse transcriptase was cloned and characterized. 14, 15) The promoter of hTERT was GC rich and lacked both TATA and CAAT boxes. Interestingly, transient expression assays revealed that transcription of hTERT was signiˆcantly activated in cancer cell lines, but repressed in normal primary cells. Over-expression of c-Myc resulted in a signiˆcant increase in transcriptional activity of the core promoter. 14, 15) Because the speciˆc therapeutic gene expression is important in cancer gene therapy, targeted cancer gene therapy has the aim to concentrate the target therapeutic gene expression into the speciˆc target tissue. Then it can minimize a secondary eŠect and maximize the therapeutic index. Therefore, the feasibility of using the hTERT promoter to induce tumor-speciˆc transgene expression in cancer gene therapy has been expected. In this paper, we investigated the possibility of the utilization of the hTERT gene promoter in gynecological cancer gene therapy using adenovirus.
Materials and Methods
Cell culture. Wi-38 (human normalˆbroblast) and QBI-293A (Quantum-Appligene, USA; a human cell line transformed by adenovirus 5 DNA) cells were grown in DMEM (GIBCO BRL, Germany) supplemented with 10z FCS (HyClone, Logan, USA), penicillin (50 units W ml), and streptomycin (50 mg W ml) in the presence of 5z CO2. NIH:OVCAR-3 (OVCAR3; ovarian cancer), A2780 (ovarian cancer), HeLa (cervical cancer) were grown in RPMI1640 (GIBCO BRL, Germany) supplemented with 10z FCS, penicillin (50 units W ml), and streptomycin (50 mg W ml) in the presence of 5z CO2. All cell lines except QBI-293A were obtained from the American Type Culture Collection (Manassas, Va).
Telomerase activity assay (TRAP assay). The telomerase activity was examined by a telomeric repeat ampliˆcation protocol (TRAP) assay with 2,000 cells using a Telosay Kit in accordance with the manufacturer's instructions (Intron, Korea). This method was based on an original method described by Kim et al.
16) The PCR products were electrophoresed in a 10z non-denaturing PAGE in TBE buŠer and stained with the Silver Staining System (Promega, USA).
RT-PCR analysis. Total RNA was isolated from each cells using RNeasy Mini kit (QIAGEN, Germany) according to the manufacturer's protocol and treated with DNase I to avoid genomic DNA contamination. cDNA was synthesized from 1 mg of RNA using the SuperScript II reverse-transcriptase assay (GIBCO BRL, Germany) with Oligo(dT)15 primer (Promega, USA). To amplify the cDNA, 2 ml aliquots of cDNA were subjected to 30 cycles of PCR (at 949 C for 1 min, at 559 C for 1 min, and at 729 C for 90 sec). hTR was ampliˆed with hTR speciˆc primer set (5?-tttgtctaaccctaactgagaagg-3? as forward and 5?-tgtgagccgagtcctgggtgcacg-3? as backward), which gave rise to 400 bp. hTERT mRNA was ampliˆed with LT5 (5?-cggaagagtctggagcaa-3?) and LT6 (5?-ggatgaagcggagtctgga-3?).
17) The e‹ciency of cDNA synthesis from each sample was estimated by PCR with GAPDH-speciˆc primers.
Luciferase assay. The selective expression of luciferase gene by hTERT promoter in tumor cells was determined by luciferase reporter plasmid using FuGENE TM 6 (Roche, Germany) according to the manufacturer's protocol. Brie‰y, 10 5 cells seeded in a 35-mm tissue culture dish were exposed to transfection mixture containing 2 mg of luciferase reporter plasmids and 0.5 mg of pSV-b-galactosidase control plasmid vector (Promega, USA) for 5 hr at 379 C. Then, 3 ml of growth media were added to the cells, followed by incubation for an additional 16 hr. The cells were harvested 48 hr after the transfection. Luciferase assays were performed according to the manufacturer's protocols. (Promega, USA). Transcriptional activity was measured with a TD-20 W 20 Luminometer (Turner Designs, Sunnyvale, CA). The Simian virus 40 (SV40) promoter (pGL3-Promoter) was used as a positive control. hTERT promoter plasmid (pGL3-hTERT) was constructed by replacing SV40 promoter with hTERT promoter. The luciferase activity of pGL3-Promoter plasmid in each cell line was considered as 100z. b-galactosidase assay was also performed with the same cell extracts to standardize for transfection e‹ciency. All of the data shown in this study were obtained from at least three independent experiments.
Cloning of hTERT promoter. The hTERT promoter region was ampliˆed by PCR using LATaq polymerase (Takara, Japan) on the HeLa genomic DNA. The hTERT forward (5?-gtcgac agtggattcgcgggcacaga-3?) and reverse (5?-aagctt agggcttcccacgtgcgcag-3?) primer, both introducing Sal I and HindIII site (underlined in the sequence respectively) were used. This region is the hTERT promoter region from -204 to ＋56, which contains core promoter and two E-boxes.
12) PCR was carried out for 35 cycles at 949 C for 1 min, at 669 C for 1 min, and at 729 C for 1 min. The PCR product was cloned into pGEM-T easy vector (Promega, USA) and digested with Sal I and HindIII. Then it was ligated with Sal I and HindIII digested pXCMVTK and named as pXhTERT-TK. Then this plasmid was digested with XbaI and ligated with XbaI digested pShuttle (Ad transfer vector) and named as pS-hT-TK (Fig. 1) . Direct dideoxynucleotide sequencing ensured a correct sequence and direction. Upper panel: The telomerase activity was assayed by a telomeric repeat ampliˆcation protocol (TRAP) assay using 2,000 cells. Lower panel: The total RNA was isolated and used for a RT-PCR in the presence of hTR, hTERT and GAPDH speciˆc primers. The PCR products were visualized after 1.5z agarose gel electrophoresis and ethidium bromide staining.
1. Wi-38, 2. HeLa, 3. OVCAR3, 4. A2780, 5. QBI-293A.
Construction of recombinant adenovirus Ad-hT-TK. The pS-hT-TK was then co-transformed with pAdEasy-1 (Quantum-Appligene, USA) into the BJ5183 E. coli cells, using electroporation methods. After selection on kanamycin plates, 40 colonies were selected and screened of recombinants by plasmid size and restriction enzyme analysis. Viral DNAs of 40 candidates were tranfected in QBI-293A cells using FuGENE TM 6 (Roche, Germany) according to the manufacturer's protocol. This constructed adenovirus vector was named as Ad-hT-TK. The constructed adenovirus were then puriˆed from the lysates of infected QBI-293A cells by two rounds of CsCl gradient centrifugation, 18) then the titers of the virus stock were determined by a plaque dilution assay.
19) The recombinant virus were stored at -809 C until use. The negative control vector (Ad5.CMV-Null; Ad-CMV) was purchased from Quantum-Appligene (Quantum-Appligene, USA). Ad-CMV is an empty vector, which contains no coding sequences between the CMV promoter and PA (poly adenylation site).
Adenovirus infection with GCV treatment in vitro. 10 5 cells were plated in six-well plates prior to infection. Ad-hT-TK or Ad-CMV adenovirus was applied in 1 ml of media at various moi, 24 hr later. Cells were incubated at 379 C for 3 hr followed by addition of 2 ml media containing of various concentration of GCV (Ganciclovir; InvivoGen, San Diego, CA, USA). Cell cultures were replenished every day with fresh medium containing GCV. All of the data shown in this study were obtained from at least three independent experiments.
Flow cytometry. The apoptotic cells were detected by an Annexin V-FITC Kit (Clontech, USA). Brie‰y, the Ad-CMV and Ad-hT-TK infected cells were rinsed with a 1× Binding buŠer and then resuspended with 200 ml of a 1× Binding buŠer. After adding 5 ml of Annexin V-FITC (20 mg W ml) and 10 ml of propidium iodide (PI; 50 mg W ml), the mixture was incubated at room temperature for 10 minutes in the dark. The cells were then analyzed by an FACSCalibur ‰ow cytometer (Becton Dickinson, Mountain View, Calif) using CELLQuest software (Becton Dickinson, San Jose, Calif).
TUNEL assay. To further determine whether treatment with Ad-hT-TK induced apoptosis, the OVCAR3 cells were stained using the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) technique with an ApopTag } Plus Peroxidase In Situ Apoptosis Detection Kit (INTERGEN, USA).
Results

Telomerase activity, hTR and hTERT expression of the cell lines
To make clear the presence of the telomerase in experimental cell lines, telomerase activity was assayed with the use of the highly sensitive TRAP assay. 16) As expected, tumor cell lines were shown strong telomerase activity, but not normal cell line (Wi-38; Fig. 2 ). To conˆrm the results of TRAP assay, we analyzed hTERT and hTR expression by RT-PCR. As expected, all cell lines expressed hTR, but hTERT mRNA was detected in TRAP assay positive cancer cell lines not normalˆbroblast Wi-38 (Fig. 2) . These results showed that telomerase activity and hTERT mRNA expression levels had a close relation in the experimental cell lines.
Variation of transcriptional activity of hTERT promoter in tumor or normal cells
To show the variation of transcriptional activity of hTERT promoter in tumor or normal cells, a transient transfection of luciferase repoter plasmid was performed (Fig. 3) . Transcriptional activity of pGL3-Promoter plasmid in each cell lines was considered as 100z. pGL3-hTERT showed signiˆcant transcriptional activity in all tumor cells lines, especially in OVCAR3 cell line about 65z of pGL3-Promoter. In contrast, there was no signiˆcant transcriptional activity in telomerase activity negative normalˆbrob- last cell line (Wi-38). These results showed that tumor cell lines had strong transcriptional activity of hTERT promoter.
Ad-hT-TK confers GCV sensitivity to tumor cells but does not aŠect normalˆbroblast
To determine cancer speciˆc cell death by Ad-hT-TK, tumor and normalˆbroblast cell lines were infected with Ad-hT-TK with or without GCV (Fig. 4) . After 6 days of infection, almost tumor cells displayed typical cell death, while did not in Wi-38 cells (Fig. 4) . To show these eŠects were MOI (Multiplicity Of Infection) and GCV dose dependent manner, OVCAR3 cell line was infected with increasing moi of Ad-hT-TK from 0 to 100 (Fig. 5) . Ad-hT-TK with GCV resulted in 86z cell death at a moi of 100 compared with Ad-hT-TK infected cells treated with PBS alone, which did not result in signiˆcant cell death. As shown in Fig. 6 , Ad-hT-TK infected OVCAR3 was sensitive to GCV treatment in a dosedependent manner. 10 mM of GCV caused 54z cell death in Ad-hT-TK infected cells, but 5¿10z cell death in Ad-CMV or mock infected cells.
Ad-hT-TK induced apoptosis of OVCAR3 cells
The apoptotic cells in the Ad-hT-TK infected cells were analyzed by a FACSCalibur ‰ow cytometer using FITC-conjugated Annexin V (Fig. 7) . The analysis using Annexin V showed that the Ad-hT-TK treated cancer cells had undergone about 55z apoptosis (Fig. 7) . Namely, the OVCAR3 cells infected with Ad-hT-TK for 6 days exhibited 64.08z apoptotic events, but only 8.74z of mock control. To conˆrm the apoptotic events by Ad-hT-TK, the OVCAR3 cells infected with Ad-hT-TK were also analyzed by a TUNEL assay. As shown Fig. 8 , a large number of darkly stained nuclei indicating apoptosis were detected. Consequently all the experi- The OVCAR3 cells were seeded at 10 5 cells in 6 well dish 24 hours prior to infection. Ad-hT-TK or Ad-CMV was infected into OVCAR3 at a moi of 50. 6 days following GCV treatment, the living cells were measured using trypan blue exclusion. The means from at least three independent experiments are shown; bars, SD. The OVCAR3 cells were infected with Ad-CMV or Ad-hT-TK at a moi of 100 with GCV (10 mM). After 6 days, the cells were stained with Annexin V and analyzed. ments clearly showed that the OVCAR3 cells infected with Ad-hT-TK underwent cell death by apoptosis.
Discussion
In cancer gene therapy, restricted expression of the therapeutic gene in tumor is important. If the therapeutic gene is expressed in all cells, the therapeutic gene will aŠect tumor and normal cells. Using the tumor speciˆc promoter system will solve this problem. However, true tumor speciˆc promoters are rare, and often these promoter useful only particular types of cancers they derived.
Although telomerase activity is undetectable in most human somatic tissues, it is generally present in highly replicative tissues and in most human cancers. As such, its exclusive expression in most tumor cells makes it a very strong candidate for targeted cancer gene therapy. There are two kind of telomerase-associated cancer gene therapy for telomerase-positive tumors. 20) First, tumor cell growth will be inhibited by direct inhibition of telomerase activity, resulting in apoptotic cell death or growth arrest. 21, 22) Telomerase consists of two major components, the RNA template (hTR) and catalytic subunit (reverse transcriptase, hTERT). hTR was considered as good therapeutic targets. 21, 22) The other approach is the telomerase-speciˆc cancer gene therapy using telomerase promoter as a means to directly kill the telomerase positive tumors.
RT-PCR analysis showed that the RNA component of telomerase (hTR) is ubiquitously expressed in most somatic cells, whereas hTERT expression is speciˆc for telomerase positive cancer cells, but not normal somatic tissue. [11] [12] [13] There are no clearly known mechanisms that control hTERT transcription. It is known that c-Myc has an important role in positive regulation of the hTERT gene activation and telomerase activation. In previous studies, c-Myc level directly in‰uenced the telomerase activity. 23) Telomerase activity in human leukemic cell lines is inhibited by antisense c-Myc oligonucleotide. 24) In hTERT promoter region, there are two typical E-boxes (CACGTG, -165 to -160 and 42 to 48), which are known as potential binding sites of the c-Myc oncoprotein. 15) To investigate the possibility of the utilization of the hTERT promoter in targeted gene therapy, we constructed adenovirus vector expressing HSV-TK controlled by the hTERT promoter for the induction of speciˆc telomerase positive cancer cell death. First, to know the existence of the telomerase, telomerase activity was assayed with TRAP assay and hTR, hTERT RT-PCR. As a result, tumor cell lines showed strong telomerase activity and speciˆc expression of hTERT, but not human normal broblast (Wi-38) (Fig. 2) . Second, adenovirus vector containing HSV-TK gene under the control of hTERT promoter was constructed. This virus was introduced into normalˆbroblast and gynecological cancer cell lines. After treatment with GCV, the morphology of the majority of the Ad-hT-TK infected cancer cells changed into apoptotic cells, with rounded-up shapes and detached from the culture dishes, and underwent cell death but not normal broblast. The growth of Ad-hT-TK infected cancer cells was signiˆcantly suppressed (Fig. 4, 5, 6 ). The GCV sensitivity of Ad-hT-TK infected telomerase positive gynecological cancer cell lines was much greater than that of mock or Ad-CMV infected cell lines (Fig. 4, 5, 6 ). Using an FACSCalibur ‰ow cytometer, the apoptotic cells within the Ad-hT-TK infected OVCAR3 cells were analyzed and it was found that the Ad-hT-TK treated cancer cells had undergone about 55z apoptosis (Fig. 7) . Also, a TUNEL assay conˆrmed that the cytotoxic eŠect of Ad-hT-TK was mainly due to apoptotic events (Fig. 8) . Therefore, it was concluded that the adenovirus Ad-hT-TK suppressed tumor cell growth and induced apoptosis and, as such, may be a useful method in suppressing tumor growth in targeted cancer gene therapy. This is theˆrst trial that used adenovirus vector, which has telomerase catalytic promoter hTERT and HSV-tk to suppress ovarian cancer cells and induce apoptotic cell death. These results support the possibility of the utilization of hTERT promoter for gynecological cancer gene therapy.
